NewcelX Ltd.
NCEL evidence brief
What we can confirm
- BioSniper Score:
- 8.2 / 10
- Market Cap:
- $19.1M
What it means
What to watch
Prepared research question
What matters most for NCEL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NCEL
NewcelX Ltd. (NCEL) is a pre-revenue biopharmaceutical company developing stem cell-based therapies for Type 1 Diabetes, ALS, and other degenerative diseases, along with a small molecule platform for narcolepsy and neuroinflammation.
Key risk: Cash insufficiency
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$19.1M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
NewcelX Ltd. (NCEL) is a pre-revenue biopharmaceutical company developing stem cell-based therapies for Type 1 Diabetes, ALS, and other degenerative diseases, along with a small molecule platform for narcolepsy and neuroinflammation.
- NewcelX has not generated any revenue from product sales and does not expect significant revenue in the near future [sec · filed 2026-04-29].
- Cash & equivalents were $2.2M as of 2025-12-31 [sec].
- Lead programs include AstroRx® (astrocyte therapy for ALS, Phase IIa) and NCEL-101 (stem cell-derived islets for Type 1 Diabetes, Phase I) [sec · filed 2026-04-29].
- The company has incurred operating losses since inception and expects continued losses for the foreseeable future [sec · filed 2026-04-29].
- NewcelX's financial position raises substantial doubt about its ability to continue as a going concern [sec · filed 2026-04-29].
What works
- NewcelX has a proprietary platform (AstroRx®) of fully differentiated astrocytes for neurodegenerative diseases, which it believes offers a competitive edge over existing MSC-based products [sec · filed 2026-04-29].
- The company is pursuing multiple therapeutic areas (T1D, ALS, narcolepsy, neuroinflammation) through both cell therapy and small molecule platforms, diversifying its pipeline [sec · filed 2026-04-29].
What to weigh
- NewcelX has never generated revenue from product sales and expects to continue incurring losses for the foreseeable future [sec · filed 2026-04-29].
- The company's current cash on hand ($2.2M as of 2025-12-31) is not believed to be sufficient to fund projected operating requirements, raising substantial doubt about its ability to continue as a going concern [sec · filed 2026-04-29].
- All product candidates are in early clinical or preclinical stages, and there is no assurance any will receive regulatory approval [sec · filed 2026-04-29].
From the filings
Quoted directly from source documents.
No revenue generated to date
“To date, NewcelX has not generated any revenue from NewcelX's development stage product candidates, AstroRx® and/or INCEL-101.”
SEC filings · April 29, 2026
Cash position raises going concern doubt
“NewcelX does not believe that its current cash on hand will be sufficient to fund its projected operating requirements. This raises substantial doubt about its ability”
SEC filings · April 29, 2026
Lead product AstroRx description
“AstroRx®, NewcelX's platform validation product, which is an off-the-shelf cryopreserved cell therapy product in clinical development for the treatment for ALS”
SEC filings · April 29, 2026
Continued losses expected
“We have incurred losses and generated negative cash flows from operations since inception and to date, we have not generated revenues”
SEC filings · April 29, 2026
Risks & what to watch (3)›
Key risks
- Cash insufficiency — Current cash of $2.2M as of 2025-12-31 is not expected to fund projected operations, raising going concern doubts [sec · filed 2026-04-29].
- No revenue history — Company has never generated product revenue and expects none in near future [sec · filed 2026-04-29].
- Regulatory uncertainty — All candidates are in early development; no assurance of regulatory approval or commercialization [sec · filed 2026-04-29].
What to watch
- Progress of AstroRx® Phase IIa clinical trial for ALS [sec · filed 2026-04-29].
- Initiation and outcomes of Phase I trial for NCEL-101 (Type 1 Diabetes) [sec · filed 2026-04-29].
- Ability to raise additional capital given cash runway concerns [sec · filed 2026-04-29].
- Any regulatory milestones or partnerships that could provide non-dilutive funding [sec · filed 2026-04-29].
Sources: SEC filings · Generated September 28, 2026 · How we verify sources →
Run NewcelX Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NewcelX Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.58
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Financials
Short Interest
- % of float
- -
- Days to cover
- —
- Shares short
- -
- Daily short volume (Oct 9, 2026)
- 48.3%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NCEL short interestFrequently asked questions
What is the AI investment thesis for NewcelX Ltd.?
NewcelX Ltd. (NCEL) is a pre-revenue biopharmaceutical company developing stem cell-based therapies for Type 1 Diabetes, ALS, and other degenerative diseases, along with a small molecule platform for narcolepsy and neuroinflammation.
Who is the CEO of NewcelX Ltd.?
Mr. Ronen Twito CPA is the chief executive officer of NewcelX Ltd. (NCEL).
Where is NewcelX Ltd. headquartered?
NewcelX Ltd. (NCEL) is headquartered in Kloten, Switzerland.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.